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Background: The rate of radiation pneumonitis (RP) for patients receiving chemoradiotherapy has been various
across studies. Whether it is related to different chemotherapy schedules used in combination with radiation
therapy were evaluated in this study. New factors associated with RP were also investigated.
Methods and materials: A total of 369 consecutive patients with Stage III non small cell lung cancer treated with
chemoradiotherapy were followed after radiotherapy (RT). Among them 262 patients received concurrent
chemoradiotherapy followed by consolidation chemotherapy and 107 patients received only sequential
chemotherapy after RT. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0.
Results: The rate of grade≥ 2 were 39.7%, 31% and 33.6% in the concurrent DP (docetaxel/cisplatin), concurrent
NP (vinorelbine/cisplatin) and sequential group, and grade≥ 3 RP were 18.4%, 9.5%, and 11.2% respectively. The
rate of grade≥ 3 RP was significantly higher in concurrent DP group than that in concurrent NP group (p = 0.04).
RP occurred earlier in concurrent DP group than that in the other two groups. There were no significant differences
in response rate among the three groups. In the multivariate analysis, age (OR = 1.99, p = 0.038 and OR = 8.90, p <
0.001), chemotherapy schedule (OR = 1.45, p = 0.041 and OR = 1.98, p = 0.013), mean lung dose(OR = 1.42, p < 0.001
and OR = 1.64, p < 0.001), and planning target volume(OR = 1.004, p = 0.001 and OR = 1.005, p = 0.021) were
predictors for both grade≥ 2 and grade≥ 3 RP. Response to treatment was a new predictor for grade≥ 3 RP only
(OR = 4.39, p = 0.034).
Conclusions: Response to treatment was found to be a new predictor for grade≥ 3 RP. Compared to concurrent NP
schedule, concurrent DP schedule achieved similar response to treatment but resulted in a higher risk of grade≥ 3 RP.
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chemoradiotherapyBackground
Approximately 30% of patients with non small cell lung
cancer (NSCLC) are diagnosed at a locally advanced stage.
In unresectable locally advanced lung cancer (LA-NSCLC),
compared to radiation therapy (RT) alone, the addition of
cisplatin based sequential chemotherapy to radiation ther-
apy resulted in modest improvement in survival [1,2].* Correspondence: gl1963516@hotmail.com
1Department of Radiation Oncology, The First Hospital of China Medical
University, No.155 Nanjing Road, Heping District, Shenyang 110001, China
Full list of author information is available at the end of the article
© 2014 Dang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Concurrent cisplatin based chemoradiotherapy showed
consistent improvement in survival compared with sequen-
tial chemoradiotherapy [3-5]. Concurrent chemoradiother-
apy (CCRT) has been regarded as the standard treatment
for unresectable LA-NSCLC patients with good perform-
ance status.
Treatment-related acute pulmonary toxicity for patients
receiving chemoradiotherapy has been various across stud-
ies (4.8% to 47%), and various chemotherapy drugs (e.g.,
taxanes, pemetrexed, irinotecan, gemcitabine) were used
(Table 1). Whether the differences in risk of radiationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Results of RP risk in clinical studies for CCRT
Study Patients (n) Treatment schedule RT dose (Gy) RP
Belani et al. [6] 74 PC + RT followed by PC 63 Grade ≥3 16%
Gandara et al. [7] 83 PE + RT followed by docetaxel 61 Grade ≥3 7%
Fournel P et al. [3] 100 PE + RT followed by NP 60 Grade ≥2 5%
Xu Y et al. [8] 21 pemetrexed/carboplatin + RT followed by pemetrexed/carboplatin NR Grade ≥3 4.8%
Bastos BR et al. [9] 32 carboplatin/irinotecan + RT followed by docetaxel 63 Grade ≥2 42%
Eroglu C et al. [10] 93 DP + RT followed by DP 66 Grade ≥3 9%
Phernambucq EC et al. [11] 83 cisplatin/gemcitabine + RT followed by PE 44-66 Grade ≥3 7.9%
Wang S et al. [12] 223 PC + RT followed by PE 63 Grade ≥3 32%
Onishi H et al. [13] 32 weekly docetaxel 60-66 Grade ≥3 47%
RP, radiation pneumonitis; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; PC, carboplatin/paclitaxel; PE, cisplatin/etoposide; DP, docetaxel/cisplatin.
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drugs or chemotherapy schedules used in combination with
RT need further investigated.
In this study, we evaluated the risk of RP in patients
with Stage III NSCLC treated with concurrent or sequen-
tial chemoradiotherapy respectively. We also analyzed




From October 2009 through August 2013, 427 consecu-
tive patients with stage III NSCLC received concurrent
or sequential chemoradiotherapy at the Radiotherapy
Department of The First Hospital of China Medical
University. These patients were recruited into our
study. Patients were staged according to the new sta-
ging system initiated by the International Association
for the Study of Lung Cancer in 2009 [14]. Patients
were excluded if they were treated with inconsistent doses
per fraction (n = 12), treated with inconsistent chemother-
apy schedules or drugs (n = 28), or a total radiation dose
less than 50 Gy (n = 17). Thus, 369 patients were followed
up prospectively after RT was completed.
Radiation therapy
All of the patients underwent three-dimensional con-
formal radiotherapy (3D-CRT) or intensity-modulated
radiotherapy (IMRT). Treatments planning computed
tomography (CT) scans with slices 5 mm thick were ob-
tained from the mandible to the lower edge of the liver be-
fore RT. The gross tumor volume (GTV) included the
primary disease as well as any involved regional lymph
nodes, which were defined as those with a short-axis
diameter of at least 1 cm on CT scan or with a short-axis
diameter of less than 1 cm but with high fluorodeoxy-
glucose (FDG) uptake on PET-CT scan. The clinical target
volume (CTV) was defined as the GTV plus a 0.6 cm-0.8 cm margin. The planning target volume (PTV) was
the CTV with 0.5–1.0 cm margin. The prescribed dose
was 60–66 Gy in 2.0-2.2 Gy daily fractions. Five fractions
a week were usually used.
Chemotherapy
262 patients received concurrent chemoradiotherapy,
and 107 patients received sequential chemoradiotherapy.
There were two chemotherapy regimens (DP and NP)
for the concurrent group. Concurrent DP regimen con-
sisted of 20–25 mg/m2/d of cisplatin on days 1–3 and
65–70 mg/m2/d of docetaxel on day 1; Concurrent NP
regimen consisted of 20–25 mg/m2/d of cisplatin on days
1–3 and 20 mg/m2/d of vinorelbine on days 1 and 5.
Chemotherapy was initiated simultaneously with RT, 1 to
2 cycles was concurrently administered with radiotherapy
and 2 to 3 cycles was administered within 4 weeks of com-
pleting RT (for 28% of patients in concurrent NP group,
NP regimen was concurrently administered with radio-
therapy, but DP regimen was administered in followed
consolidation chemotherapy). The chemotherapy regimen
for sequential group was DP (20–25 mg/m2/d of cisplatin
on days 1–3 and 70–75 mg/m2/d of docetaxel on day 1);
chemotherapy was initiated 2 to 4 weeks after RT, 3 to
4 cycles was administered, and every 3–4 week a cycle.
Dose-volume histogram (DVH) parameters
The total normal lung volume was defined as the total
lung volume minus the primary CTV and the volume of
the trachea and main bronchi. The following parameters
were extracted for modeling: V20 (total lung volume re-
ceiving ≥20 Gy), mean lung dose (MLD), mean heart dose
(MHD) and planning target volume (PTV).
Evaluation and follow-up
Early RP and late lung fibrosis are different stages of
radiation-induced lung injury. Early RP usually occurs 1 to
6 months after RT, whereas late lung fibrosis usually
Table 2 Clinical and treatment characteristics (n = 369)
Characteristics No. of patients
Sex (male/female) 263(71%)/106(29%)
Age (≥70/<70) 117(32%)/252(68%)








Smoking history (yes/no) 230(62%)/139(38%)





CTV, clinical target volume; CR, complete response; PR, partial response;
DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin; 3D-CRT, three-dimensional
conformal radiotherapy; IMRT, intensity-modulated radiotherapy.
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in early RP, we used six months as the cut-off for
diagnosis.
Patients were evaluated by radiation oncologists
weekly during radiation, and once a month until six
months after RT. A chest CT scan was performed at
each follow-up evaluation after completion of radiother-
apy. A diagnosis of RP was made with consensus by at
least two radiation oncologists based on clinical symp-
toms, with or without radiographic infiltrate changes.
Findings on a CT image of RP include a diffuse haziness
or fuzziness in the areas of the irradiated lung, which
may coalesce to a form a relatively sharp edge corre-
sponding to the shape and size of the radiation field.
These radiographic changes in RP may also reveal out-
side the radiation field. The symptoms of RP are dry
cough, low-grade fever, chest pain, and shortness of
breath. Cases difficult to diagnose were referred to re-
spiratory or circulation physicians to exclude other dis-
eases. Patients with a diagnosis of grade ≥ 2 RP were
required to have an immediate intervention, including
oral or intravenous steroids, oxygen, and antibiotics.
Grading was conducted according to Common Termin-
ology Criteria for Adverse Events version 4.0 [15].
Response Evaluation Criteria in Solid Tumors (RECIST)
was used to evaluate treatment response 4–6 weeks after
the completion of the treatments.Statistical analysis
Grade2 or above RP were counted as events. Statistical
analysis was performed using SPSS 13.0 statistical soft-
ware (Chicago, IL). Univariate analysis was performed
to evaluate the influence of patient characteristics and
dose-volume variables on RP risk. The independent
samples t-test, analysis of variance or the χ2-test were
used for univariate analysis. Multivariate analysis
was performed using logistic regression model (enter
method) containing all variables that attained or
trended toward univariate statistical significance (p ≤
0.3) in Table 2. The receiver operating characteristic
(ROC) curve was used to identify the c-statistics for
each dose-volume variable and the models. The correl-
ation between dose-volume variables was tested with
Pearson Correlation Coefficient. All statistical tests
were 2-sided and p ≤ 0.05 was considered statistically
significant.Results
Four patients died of grade 5 RP (three in concurrent
DP group, and one in concurrent NP group). All other
patients were successfully followed up through the end
point of six months after RT.Response to treatment
The response rates (CR + PR) were 78.7% in concurrent DP,
77% in concurrent NP, and 71% in sequential group re-
spectively, which were not significantly different (P = 0.585).
Evaluation of RP
RP occurred earlier in concurrent DP group (2.4 ±
1.1 months after RT) than that in concurrent NP (2.9 ±
1.2 months after RT) and sequential group (3.2 ± 1.2 months
after RT) (p < 0.05 for each comparison).
The rate of grade ≥ 2 were 39.7%, 31% and 33.6% in the
concurrent DP, concurrent NP and sequential group, and
grade ≥ 3 RP were 18.4%, 9.5%, and 11.2% respectively. The
rate of grade ≥ 3 RP was significantly higher in concurrent
DP group than that in concurrent NP group (p = 0.04).
Patient characteristics
Patient characteristics were listed in Table 2. The results
of univariate analysis were shown in Table 3. The results
of the multivariate analysis suggested that age and
chemotherapy schedule were predictors for both grade ≥
2 (OR = 1.99, p = 0.038; OR = 1.45, p = 0.041) and grade ≥
3 RP (OR = 8.90, p = 0.000; OR = 1.98, p = 0.013). Re-
sponse to treatment was a predictor for grade ≥ 3 RP
only (OR = 4.39, p = 0.034) (Table 4).
Dose-volume factors
In univariate analysis, the dose-volume variables of V20,
MLD, MHD and PTV were all significantly associated
with RP (p = 0.000 for each comparison) (Table 3). C-
statistics for each dose-volume variable were shown in
Table 5. Due to the linear correlation between MLD and
Table 3 Demographic and tumor characteristics and dose-volume factors of patients by RP status
Variables Grade 0-1 Grade 2 Grade ≥ 3 p-value
n = 240 n = 80 n = 49
Sex (male/female) 174/66 57/23 32/17 0.598
Age (≥70/<70) 72/168 22/58 23/26 0.044
Performance status (0/1/2) 74/157/9 24/55/1 16/32/1 0.808
Stage (IIIA/IIIB) 159/81 46/34 29/20 0.299
Pathology (squamous/adenocarcinoma/others) 145/81/14 54/23/3 30/15/4 0.723
CTV location
Left/right 115/123 48/32 30/19 0.083
Upper/lower 164/76 48/32 23/26 0.013
Smoking history (Y/N) 153/87 49/31 28/21 0.668
Response (PR + CR/others) 173/67 62/18 45/4 0.012
RT (3D-CRT/IMRT) 189/51 63/17 36/13 0.708
Chemotherapy schedule (concurrent DP/concurrent NP/sequential) 82/87/71 29/27/24 25/12/12 0.268
PTV 396.67 ± 107.18 460.59 ± 105.02 514.92 ± 98.47 0.000
V20 0.28 ± 0.09 0.37 ± 0.09 0.43 ± 0.10 0.000
MLD 14.15 ± 3.26 17.71 ± 3.28 21.40 ± 3.48 0.000
MHD 15.24 ± 7.16 20.33 ± 6.36 22.31 ± 5.62 0.000
RP, radiation pneumonitis; CTV, clinical target volume; PTV, planning target volume; V20, lung volume receiving ≥20Gy; MLD, mean lung dose; MHD, mean heart
dose; CR, complete response; PR, partial response; DP, docetaxel/cisplatin; NP, vinorelbine/cisplatin; 3D-CRT, three-dimensional conformal radiotherapy; IMRT,
intensity-modulated radiotherapy.
Table 4 C-statistics for dose-volume variables
Variables Grade ≥ 2 Grade ≥ 3
c-statistics 95% CI c-statistics 95% CI
V20 0.808 0.761 ~ 0.855 0.827 0.771-0.883
MLD 0.838 0.794 ~ 0.881 0.897 0.854-0.939
MHD 0.727 0.674-0.779 0.725 0.655-0.796
PTV 0.720 0.667-0.774 0.757 0.692-0.822
PTV, planning target volume; V20, lung volume receiving ≥20 Gy; MLD, mean
lung dose; MHD, mean heart dose.
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statistic than V20 (grade ≥ 2: 0.838 vs. 0.808; grade ≥ 3:
0.897 vs. 0.827), V20 was removed from the logistic re-
gression model. MLD, MHD and PTV were included
in the multivariate logistic regression analysis. The re-
sults of the multivariate analysis suggested that MLD
and PTV were predictors for both grade ≥ 2 (OR = 1.42,
p < 0.001 and OR = 1.004, p = 0.001) and grade ≥ 3 RP
(OR = 1.64, p < 0.001 and OR = 1.005, p = 0.021) (Table 4).
The c-statistic was 0.86 for the Grade ≥ 2 model and 0.94
for the Grade ≥ 3 model, indicating good discrimination.
Discussion
Combination of chemotherapy and RT has been well re-
ported increasing the risk of pulmonary injury, either
sequential [16] or concurrent [12,13]. Weekly docetaxel
with concurrent conventional radiotherapy resulted in
47% grade ≥3 RP [13]; Carboplatin plus taxanes with
concurrent 3D-CRT resulted in 32% grade ≥3 RP [12].
However, there are also inconsistent results. PE regi-
men showed 5% grade ≥2 RP [3], and pemetrexed plus
carboplatin regimen showing 4.8% grade ≥3 RP [8]
with concurrent 3D-CRT in two Phase III trials. Data
from a large meta-analysis of predictors of RP showed
that concurrent carboplatin/paclitaxel regimen was as-
sociated with a high risk of RP compared with concur-
rent cisplatin/etoposide regimen [17]. In this study, wecompared the risk of RP among concurrent DP, con-
current NP and sequential group respectively. Our data
showed a higher rate of grade ≥ 3 RP for concurrent DP
schedule (18.4%) than that for concurrent NP schedule
(9.5%)(p < 0.05), while the risk of RP for sequential
schedule was moderate (11.2% for grade ≥ 3). Chemo-
therapy schedule was an independent predictor for
grade ≥ 3 RP (OR = 1.98, p = 0.013). The results above
suggested that differences in RP risk across studies
might be related to different chemotherapy schedule
or drugs used in chemoradiotherapy. Thus care should
be taken when chemotherapy schedule or drugs are
selected in combination with RT to ensure that treat-
ment toxicities do not overwhelm the potential bene-
fits of treatment.
Table 5 Multivariate logistic regression analysis of factors associated with RP
Variables Grade ≥ 2 Grade ≥ 3
OR 95% CI p-value OR 95% CI p-value
Age (≥70/<70) 1.99 1.04-3.80 0.038 8.90 3.23-24.51 <0.001
Chemotherapy schedule (concurrent DP/
concurrent NP/sequential)
1.45 1.01-2.07 0.041 1.98 1.16-3.39 0.013
Response (PR + CR/others) 1.06 0.53-2.14 0.870 4.39 1.12-17.24 0.034
PTV 1.004 1.002-1.007 0.001 1.005 1.001-1.009 0.021
MLD 1.42 1.28-1.58 <0.001 1.64 1.40-1.93 <0.001
Stage (IIIA/IIIB) 1.28 0.72-2.26 0.405 0.85 0.36-2.01 0.705
CTV location (left/right) 0.75 0.43-1.32 0.32 1.43 0.60-3.44 0.419
CTV location (upper/lower) 0.68 0.33-1.40 0.29 0.74 0.25-2.18 0.581
RP, radiation pneumonitis; PTV, planning target volume; MLD, mean lung dose; CR, complete response; PR, partial response; DP, docetaxel/cisplatin; NP,
vinorelbine/cisplatin; CTV, clinical target volume.
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rate among concurrent DP (78.7%), concurrent NP
(77%) and sequential group (71%) in this study (P =
0.585). However, it was interesting to note a significantly
higher rate of RP for patients with good response to
treatment (CR or PR) than others (p < 0.05) (Table 3),
and the response to treatment was an independent pre-
dictor for grade ≥3 RP in Multivariate analysis(OR =
4.39, p = 0.034) (Table 4). To our knowledge, no study
has been reported to analyze the correlation between the
response to treatment and RP. How to explain the re-
sult? Most of our patients were with relatively large
tumor size(T3), and treated with concurrent DP or con-
current NP RT. Chemotherapy drugs thought to be
radiosensitization might lead to rapid response to treat-
ment during process of RT. If treatment planning were
not modified in time, the original GTV would contain
part of lung leading to higher dose to larger volume of
lung. If so, modifying treatment planning in time during
process of RT for patients receiving concurrent chemo-
radiotherapy would become definitely necessary.
MLD and age were predictors for RP in this study,
which were consistent with the literature. Results from
studies about the correlation between PTV and the risk
of RP remain inconsistent [18,19]. It might be related to
differences in total lung volume of different patients;
that is, a lower percentage of lung would be irradiated in
patients with a larger lung volume and a higher percent
of lung would be irradiated in patients with a smaller
lung volume when their PTV were equal. PTV was a
predictor for both grade ≥ 2 and grade ≥ 3 RP in our
study, however, the correlation was weak (OR = 1.004
and OR = 1.005, respectively) (Table 4).
Rodrigues G, et al. [20] performed a systematic review
of the predictive ability of various dose–volume variables
(Vdose, MLD) for RP and found that most studies did
show an association between dose–volume variables and
RP risk, however, the predictive ability was generallypoor. In this study, dose–volume variables such as MLD
and V20 had the higher c-statistics for Grade ≥ 2 or
Grade ≥ 3 RP, indicating good discrimination (Table 5).
In this study, RP occurred earlier in concurrent DP
group than that in concurrent NP or sequential group
(p < 0.05). It was probably due to damage to lung by do-
cetaxel used in concurrent RT process.
Conclusions
Compared to concurrent NP schedule, concurrent DP
schedule achieved similar response to treatment but re-
sulted in a higher risk of RP. Besides age, PTV, and
MLD, response to treatment and chemotherapy schedule
were found to be new predictors for RP.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JD and GL are lead authors who participated in manuscript drafting, table
creation, and manuscript revision. SZ performed statistical analyses. SZ
participated in the clinical coordination and aided in data collection. LY is
the dosimetrist who contributed dosimetric data and tables. All authors read
and approved the final manuscript.Acknowledgments
The study was supported by Liaoning province science and technology plan
projects, project number: 2012225016.
Author details
1Department of Radiation Oncology, The First Hospital of China Medical
University, No.155 Nanjing Road, Heping District, Shenyang 110001, China.
2Department of Nursing, China Medical University, Shenyang 110001, China.
Received: 31 March 2014 Accepted: 23 July 2014
Published: 30 July 2014
Dang et al. Radiation Oncology 2014, 9:172 Page 6 of 6
http://www.ro-journal.com/content/9/1/172References
1. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR: Improved
survival in stage III nonYsmall-cell lung cancer: seven-year follow-up of
cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996,
88:1210–1215.
2. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Douillard JY, Tarayre M,
Lacombe-Terrier MJ, Laplanche A: Radiotherapy alone versus combined
chemotherapy and radiotherapy in nonresectable nonYsmallcell lung
cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst
1991, 83:417–423.
3. Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A,
Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex
F, Pérol M, Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français
de Pneumo-Cancérologie: Randomized phase III trial of sequential
chemoradiotherapy compared with concurrent chemoradiotherapy in
locally advanced nonYsmall-cell Lung cancer: groupe Lyon-Saint-Etienne
d’Oncologie thoracique-groupe francais de pneumo-cancerologie NPC
95–01 study. J Clin Oncol 2005, 23:5910–5917.
4. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B,
Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD:
Sequential vs. concurrent chemoradiation for stage III non-small cell lung
cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011,
103:1452–1460.
5. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P,
Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC,
Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP:
Meta-analysis of concomitant versus sequential radiochemotherapy in locally
advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181–2190.
6. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr:
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for
locally advanced non-small-cell lung cancer: a randomized phase II locally
advanced multi-modality protocol. J Clin Oncol 2005, 23:5883–5891.
7. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H,
Gumerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R, Southwest
Oncology Group: Consolidation docetaxel after concurrent
chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II
southwest oncology group study S9504. J Clin Oncol 2003, 21:2004–2010.
8. Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, Du X, Zheng Y, Qiu G: Concomitant
chemoradiotherapy using pemetrexed and carboplatin for unresectable
stage III non-small cell lung cancer (NSCLC): preliminary results of a
phase II study. Lung Cancer 2011, 72:327–332.
9. Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, Santos ES,
Lopes G, Raez LE: Efficacy and toxicity of chemoradiotherapy with
carboplatin and irinotecan followed by consolidation docetaxel for
unresectable stage III non-small cell lung cancer. J Thorac Oncol 2010,
5:533–539.
10. Eroglu C, Orhan O, Unal D, Dogu GG, Karaca H, Dikilitas M, Oztürk A, Ozkan M,
Kaplan B: Concomitant chemoradiotherapy with docetaxel and cisplatin
followed by consolidation chemotherapy in locally advanced unresectable
non-small cell lung cancer. Ann Thorac Med 2013, 8:109–115.
11. Phernambucq EC, Spoelstra FO, Verbakel WF, Postmus PE, Melissant CF,
van den Brink KI M, Frings V, van de Ven PM, Smit EF, Senan S: Outcomes
of concurrent chemoradiotherapy in patients with stage III non-small-
cell lung cancer and significant comorbidity. Ann Oncol 2011, 22:132–138.
12. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Chen J, Du X, Zheng Y, Qiu G:
Analysis of clinical and dosimetric factors associated with treatment-related
pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC)
treated with concurrent chemotherapy and three-dimensional conformal
radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006, 66:1399–1407.
13. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T,
Nishikawa K, Ishihara H: Concurrent two-dimensional radiotherapy and
weekly docetaxel in the treatment of stage III non-small cell lung cancer: a
good local response but no good survival due to radiation pneumonitis.
Lung Cancer 2003, 40:79–84.
14. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R,
Postmus PE, Rusch V, Sobin L, International Association for the Study of
Lung Cancer International Staging Committee; Participating Institutions:
International association for the study of lung cancer international
staging committee; participating institutions. The IASLC lung cancer staging
project: proposals for the revision of the TNM stage groupings in theforthcoming (seventh) edition of the TNM classification of malignant
tumours. J Thorac Oncol 2007, 2:706–714.
15. Gravs PR, Siddiqui F, Anscher MS, Movsas B: Radiation pulmonary toxicity:
from mechanisms to management. Semin Radiat Oncol 2010, 20:201–207.
16. Dang J, Li G, Lu XB, Yao L, Zhang S, Yu Z: A nalysis of related factors
associated with radiation pneumonitis in patients with locally advanced
non-small-cell lung cancer treated with three-dimensional conformal
radiotherapy. J Cancer Res Clin Oncol 2010, 136:1169–1178.
17. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD,
Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G: Predicting
radiation pneumonitis after chemoradiation therapy for lung cancer: an
international individual patient data meta-analysis. Int J Radiat Oncol Biol
Phys 2013, 85:444–450.
18. Sunyach MP, Falchero L, Pommier P, Perol M, Arpin D, Vincent M, Boutry D,
Rebatu P, Ginestet C, Martel-Lafay I, Perol D, Carrie C: Prospective evaluation
of early lung toxicity following three-dimensional conformal radiation
therapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol
Biol Phys 2000, 48:459–463.
19. Huang EX, Hope AJ, Lindsay PE, Trovo M, El Naqa I, Deasy JO, Bradley JD:
Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol
2011, 50:51–60.
20. Rodrigues G, Lock M, D’Souza D, Yu E, Van Dyk J: Prediction of radiation
pneumonitis by dose - volume histogram parameters in lung cancer-a
systematic review. Radiother Oncol 2004, 71:127–138.
doi:10.1186/1748-717X-9-172
Cite this article as: Dang et al.: Risk and predictors for early radiation
pneumonitis in patients with stage III non-small cell lung cancer treated
with concurrent or sequential chemoradiotherapy. Radiation Oncology
2014 9:172.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
